The Pathophysiology of Cardiac Hypertrophy and Heart Failure

William E. Stansfield; Mark Ranek; Avani Pendse; Jonathan C. Schisler; Shaobin Wang; Thomas Pulinilkunnil; Monte S. Willis

doi:10.1016/B978-0-12-405206-2.00004-1

The Pathophysiology of Cardiac Hypertrophy and Heart Failure

William E. Stansfield, Mark Ranek, Avani Pendse, Jonathan C. Schisler, Shaobin Wang, Thomas Pulinilkunnil, Monte S. Willis

School of Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter

13 Scopus citations

Abstract

Left ventricular hypertrophy (LVH) is one of the most common cardiovascular diseases; the estimated prevalence is 20% in the general population. In spite of being one of the greatest independent risk factors for cardiovascular morbidity and mortality, it remains essentially untreated. In this chapter, we review the complex interplay of physiologic systems that give rise to pathologic hypertrophy and heart failure. We explore the hierarchy of intra- and intercellular signaling systems that converge to produce the hypertrophic phenotype. Lastly, we consider novel access points within these systems that may represent new therapeutic windows for pharmacologic intervention.

Original language	English (US)
Title of host publication	Cellular and Molecular Pathobiology of Cardiovascular Disease
Publisher	Elsevier Inc.
Pages	51-78
Number of pages	28
ISBN (Print)	9780124052062
DOIs	https://doi.org/10.1016/B978-0-12-405206-2.00004-1
State	Published - Jan 2014

Keywords

Calcineurin
Congestive heart failure (CHF)
FAK
GPCR
HDAC
Hypertrophy
Left ventricular hypertrophy (LVH)
MAPK
MTOR
MicroRNA
Mitochondria
NFAT
NO
Pathologic hypertrophy
Proteasome
Reactive oxygen species (ROS)
SRF
TNF
Ubiquitin

ASJC Scopus subject areas

General Dentistry
General Medicine

Access to Document

10.1016/B978-0-12-405206-2.00004-1

Cite this

@inbook{ef9fddbcc7b54dcbb07ed3f1a5154046,

title = "The Pathophysiology of Cardiac Hypertrophy and Heart Failure",

abstract = "Left ventricular hypertrophy (LVH) is one of the most common cardiovascular diseases; the estimated prevalence is 20% in the general population. In spite of being one of the greatest independent risk factors for cardiovascular morbidity and mortality, it remains essentially untreated. In this chapter, we review the complex interplay of physiologic systems that give rise to pathologic hypertrophy and heart failure. We explore the hierarchy of intra- and intercellular signaling systems that converge to produce the hypertrophic phenotype. Lastly, we consider novel access points within these systems that may represent new therapeutic windows for pharmacologic intervention.",

keywords = "Calcineurin, Congestive heart failure (CHF), FAK, GPCR, HDAC, Hypertrophy, Left ventricular hypertrophy (LVH), MAPK, MTOR, MicroRNA, Mitochondria, NFAT, NO, Pathologic hypertrophy, Proteasome, Reactive oxygen species (ROS), SRF, TNF, Ubiquitin",

author = "Stansfield, {William E.} and Mark Ranek and Avani Pendse and Schisler, {Jonathan C.} and Shaobin Wang and Thomas Pulinilkunnil and Willis, {Monte S.}",

year = "2014",

month = jan,

doi = "10.1016/B978-0-12-405206-2.00004-1",

language = "English (US)",

isbn = "9780124052062",

pages = "51--78",

booktitle = "Cellular and Molecular Pathobiology of Cardiovascular Disease",

publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - The Pathophysiology of Cardiac Hypertrophy and Heart Failure

AU - Stansfield, William E.

AU - Ranek, Mark

AU - Pendse, Avani

AU - Schisler, Jonathan C.

AU - Wang, Shaobin

AU - Pulinilkunnil, Thomas

AU - Willis, Monte S.

PY - 2014/1

Y1 - 2014/1

N2 - Left ventricular hypertrophy (LVH) is one of the most common cardiovascular diseases; the estimated prevalence is 20% in the general population. In spite of being one of the greatest independent risk factors for cardiovascular morbidity and mortality, it remains essentially untreated. In this chapter, we review the complex interplay of physiologic systems that give rise to pathologic hypertrophy and heart failure. We explore the hierarchy of intra- and intercellular signaling systems that converge to produce the hypertrophic phenotype. Lastly, we consider novel access points within these systems that may represent new therapeutic windows for pharmacologic intervention.

AB - Left ventricular hypertrophy (LVH) is one of the most common cardiovascular diseases; the estimated prevalence is 20% in the general population. In spite of being one of the greatest independent risk factors for cardiovascular morbidity and mortality, it remains essentially untreated. In this chapter, we review the complex interplay of physiologic systems that give rise to pathologic hypertrophy and heart failure. We explore the hierarchy of intra- and intercellular signaling systems that converge to produce the hypertrophic phenotype. Lastly, we consider novel access points within these systems that may represent new therapeutic windows for pharmacologic intervention.

KW - Calcineurin

KW - Congestive heart failure (CHF)

KW - FAK

KW - GPCR

KW - HDAC

KW - Hypertrophy

KW - Left ventricular hypertrophy (LVH)

KW - MAPK

KW - MTOR

KW - MicroRNA

KW - Mitochondria

KW - NFAT

KW - NO

KW - Pathologic hypertrophy

KW - Proteasome

KW - Reactive oxygen species (ROS)

KW - SRF

KW - TNF

KW - Ubiquitin

UR - http://www.scopus.com/inward/record.url?scp=84902749129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902749129&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-405206-2.00004-1

DO - 10.1016/B978-0-12-405206-2.00004-1

M3 - Chapter

AN - SCOPUS:84902749129

SN - 9780124052062

SP - 51

EP - 78

BT - Cellular and Molecular Pathobiology of Cardiovascular Disease

PB - Elsevier Inc.

ER -

The Pathophysiology of Cardiac Hypertrophy and Heart Failure

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this